<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03175744</url>
  </required_header>
  <id_info>
    <org_study_id>D032150</org_study_id>
    <nct_id>NCT03175744</nct_id>
  </id_info>
  <brief_title>Stellarex DCB Versus Standard Balloon Angioplasty for Treatment of Below-The-Knee (BTK) Arteries</brief_title>
  <official_title>Prospective, Randomized, Multi-Center Study to Evaluate Treatment of Subjects With Occlusive Disease With a Novel Paclitaxel-Coated Angioplasty Balloon in Below-The-Knee (BTK) Arteries - ILLUMENATE BTK</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectranetics Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spectranetics Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to demonstrate the safety and effectiveness of the Stellarex DCB for the
      treatment of stenosis or occlusions of below-the-knee arteries.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 24, 2017</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from Major Adverse Limb Event (MALE)</measure>
    <time_frame>30 days</time_frame>
    <description>Composite of major amputation or major reintervention on a per patient basis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from Perioperative Death (POD)</measure>
    <time_frame>30 days</time_frame>
    <description>Death on a per patient basis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patency</measure>
    <time_frame>6 months</time_frame>
    <description>Freedom from target lesion occlusion and clinically driven target lesion reintervention and freedom from major amputation on a per patient basis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Limb Salvage</measure>
    <time_frame>6 months</time_frame>
    <description>Freedom from target lesion occlusion and clinically driven target lesion reintervention and freedom from major amputation on a per patient basis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinically-driven target lesion revascularization</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of clinically-driven target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse event rates</measure>
    <time_frame>6 months</time_frame>
    <description>Composite rate of all-cause death, major amputation and clinically driven target lesion reintervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patency rate</measure>
    <time_frame>6 months</time_frame>
    <description>Absence of target lesion occlusion and freedom from clinically-driven target lesion reintervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">354</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>Stellarex DCB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spectranetics Stellarex Drug Coated Balloon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTA Catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Uncoated Balloon Angioplasty Catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stellarex DCB</intervention_name>
    <description>Intervention with the Stellarex DCB</description>
    <arm_group_label>Stellarex DCB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PTA Catheter</intervention_name>
    <description>Intervention with an uncoated Standard PTA</description>
    <arm_group_label>PTA Catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Rutherford Clinical Category 4-5

          -  Life expectancy &gt; 1 year

          -  Significant stenosis â‰¥70%

          -  Patent inflow artery

          -  Target vessel(s) diameter between 2 and 4 mm

          -  Target vessel(s) reconstitute(s) at the ankle

        Exclusion Criteria:

          -  Pregnant or planning to become pregnant

          -  History of stroke within 3 months

          -  Planned major amputation

          -  eGFR &lt;30

          -  Acute limb ischemia

          -  Prior stent placement in target lesion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Gray, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lankenau Heart Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mahmood K Razavi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vascular and Interventional Specialists of Orange</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dierk Scheinert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Leipzig</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janiece Rutherford</last_name>
    <phone>1-763-955-1143</phone>
    <email>janiece.rutherford@spnc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>LKH Universitatsklinik Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Brodmann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ZOL St. jan</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wouter Lansink, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Vermassen, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2017</study_first_submitted>
  <study_first_submitted_qc>June 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2017</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

